Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploring Lenvatinib Plus TACE Versus Sorafenib Plus TACE for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Efficacy, Safety and Outcome Analysis

Next Previous
Trial Profile

Exploring Lenvatinib Plus TACE Versus Sorafenib Plus TACE for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Efficacy, Safety and Outcome Analysis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use

Most Recent Events

  • 19 Jul 2021 Planned End Date changed from 1 Apr 2021 to 1 Dec 2021.
  • 19 Jul 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Aug 2021.
  • 08 Jul 2021 Results (n=64) comparing the efficacy and safety of TACE plus lenvatinib versus TACE plus sorafenib in patients with unresectable HCC and portal vein tumor thrombus, published in the Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top